# Effect of Harvoni on Proteinuria and eGFR in Hepatitis C Virus Associated Chronic Kidney Disease (CKD)

> **NCT02503735** · NA · TERMINATED · sponsor: **Massachusetts General Hospital** · enrollment: 14 (actual)

## Conditions studied

- Hepatitis C
- Chronic Kidney Disease

## Interventions

- **DRUG:** Sofosbuvir/Ledipasvir FDC

## Key facts

- **NCT ID:** NCT02503735
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-07-15
- **Primary completion:** 2017-09
- **Final completion:** 2019-05
- **Target enrollment:** 14 (ACTUAL)
- **Why stopped:** Unable to meet enrollment goal
- **Last updated:** 2020-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02503735

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02503735, "Effect of Harvoni on Proteinuria and eGFR in Hepatitis C Virus Associated Chronic Kidney Disease (CKD)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02503735. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*